Black Diamond Therapeutics (BDTX) Accumulated Expenses (2018 - 2026)

Black Diamond Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $11.6 million for Q1 2026.

• Quarterly Accumulated Expenses fell 18.67% year-over-year to $11.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.6 million (down 18.67% YoY) and the FY2025 annual result came in at $15.2 million, down 8.54% from the prior year.
• Accumulated Expenses was $11.6 million for Q1 2026 at Black Diamond Therapeutics, down from $15.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $18.8 million in Q3 2024 and bottomed at $9.8 million in Q1 2023.
• A 5-year average of $15.1 million and a median of $15.4 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses tumbled 44.27% — and 2024, when it surged 59.96%.
• Black Diamond Therapeutics' Accumulated Expenses stood at $13.4 million in 2022, then advanced by 29.42% to $17.3 million in 2023, then decreased by 4.36% to $16.6 million in 2024, then fell by 8.54% to $15.2 million in 2025, then fell by 23.67% to $11.6 million in 2026.
• Business Quant data shows BDTX's Accumulated Expenses at $11.6 million in Q1 2026, $15.2 million in Q4 2025, and $14.6 million in Q3 2025.